ARCHIVES

Modality Combo Decreases Prostate Cancer Recurrence

This article is from The Cancer Letter archive.

Vol. 27 No. 8 | August 27, 2004

Download PDF Visit The Full Archive

Related Articles

Patient Advocacy: FDA, NCI Developing Methods For Naming Survivors To Boards

February 7, 1997

Data-Dredging? Don’t Try It, FDA Says.

May 11, 2007

Clinical Trials Approved By NCI CTEP During July

August 30, 2002

BCDDP Follow Up To Cost $1.6 Million annually For Five Years Okayed; Limited To 59,000 Women

November 3, 1978

Patient Advocacy: Survivorship Programs Win Funds To form Model Programs

December 13, 1996

Lombardi Recruits Adams-Campbell.

October 3, 2008